• Francisco M Calderon Novoa, Esteban Masino, Lucas Caram, Ezequiel Mauro, Leila Haddad, Adrián Gadano, Sebastián Marciano, Jimena Vicens, Valeria Aliperti, Cristina Elizondo, Vanina Pagotto, Juan Carlos Spina, Ricardo García Mónaco, Eduardo Mullen, Victoria Ardiles, Eduardo De Santibañes, Juan Pekolj, and Martín De Santibañes.
• Servicio de Cirugía General, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
• Medicina (B Aires). 2022 Jan 1; 82 (5): 695-707.

AbstractHepatocellular carcinoma is the most common primary liver tumor, with 905 677 diagnosed cases and 830 180 deaths, in 2020 worldwide. In Argentina, it accounts for the 9th cause of death for cancer in men and the 10th in women. Unlike other highly-prevalent tumors, scientific evidence for most therapeutic options is limited mainly to small cohorts and retrospective studies. The aim of this study is to characterize and describe epidemiologically patients with diagnosis of hepatocellular carcinoma in the Italian Hospital of Buenos Aires during a 12-year period. Overall survival for our cohort was 58%, 46%, and 36% at 1, 3 and 5 years respectively. Average survival for patients receiving palliative treatment was 5 months, while for those who received either non-curative or curative treatment was 23 and 75 months respectively. Recurrence-free survival for those patients who underwent a curative treatment was 89%, 76% y 61% at 1, 3 and 5 years. A thorough analysis of etiology, risk factors, incidence, mortality and treatment was made. The study's importance lies in its large sample size, quantity and quality of data, and will most certainly stimulate the development of local studies in hepatocellular carcinoma.

21 keywords...

hide…